Kathy Johnson  Weiler net worth and biography

Kathy Weiler Biography and Net Worth

Director of AxoGen

Ms. Weiler has served on our Board of Directors since December 2023. She is the Chief Transformation Officer at Solventum leading one of the largest medtech transformations in the industry. She is also focused on key strategic opportunities across the enterprise with specific focus on the HIS and MedSurg businesses. Previously, Ms. Weiler was Amwell’s Executive Vice President, Chief Commercial and Growth Officer. In her role, she oversaw the company’s growth strategy, driving strategic initiatives and leading business development, sales and account management, commercial enablement, marketing, and strategic and channel partnership teams. Prior to Amwell, Kathy served as Chief Consumer Officer at Optum, where she led consumerism across the enterprise. Preceding that, she was Chief Consumer Strategy Officer at UnitedHealth Group and the Chief Marketing and Experience Officer of Optum Health, leading marketing efforts for Optum Care and Optum’s Population Health Solutions, Complex Care Management, Medical Benefits Management, Behavioral Health, Prevention and Financial Services businesses. Kathy also served as Chief Marketing and Product Officer at Blue Cross and Blue Shield of Massachusetts, where she drove strategic growth and retention business objectives. Weiler spent her earlier career with multiple financial services organizations. She was Chief Marketing Officer of Fidelity Investments FAS business and held senior marketing leadership roles at BNY Mellon/Pershing and The Hartford. Kathy holds a B.A. from Bowdoin College and an M.A. in International Economics and Finance from Brandeis University.

What is Kathy Johnson Weiler's net worth?

The estimated net worth of Kathy Johnson Weiler is at least $6.52 million as of September 3rd, 2024. Weiler owns 188,027 shares of AxoGen stock worth more than $6,518,896 as of February 3rd. This net worth approximation does not reflect any other assets that Weiler may own. Learn More about Kathy Johnson Weiler's net worth.

How do I contact Kathy Johnson Weiler?

The corporate mailing address for Weiler and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at [email protected]. Learn More on Kathy Johnson Weiler's contact information.

Has Kathy Johnson Weiler been buying or selling shares of AxoGen?

Kathy Johnson Weiler has not been actively trading shares of AxoGen during the last quarter. Most recently, Kathy Johnson Weiler sold 46,653 shares of the business's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $29.55, for a transaction totalling $1,378,596.15. Learn More on Kathy Johnson Weiler's trading history.

Who are AxoGen's active insiders?

AxoGen's insider roster includes Marc Began (EVP), P Burke (Director), Michael Dale (CEO), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Lindsey Hartley (CFO), John Johnson (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Paul Thomas (Director), Joseph Tyndall (Director), Kathy Weiler (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.

Are insiders buying or selling shares of AxoGen?

In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 475,453 shares worth more than $12,603,234.48. The most recent insider tranaction occured on December, 16th when Director Amy Mcbride Wendell sold 43,684 shares worth more than $1,280,378.04. Insiders at AxoGen own 2.8% of the company. Learn More about insider trades at AxoGen.

Information on this page was last updated on 12/16/2025.

Kathy Johnson Weiler Insider Trading History at AxoGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2025Sell46,653$29.55$1,378,596.15View SEC Filing Icon  
See Full Table

Kathy Johnson Weiler Buying and Selling Activity at AxoGen

This chart shows Kathy Johnson Weiler's buying and selling at AxoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AxoGen Company Overview

AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $35.01
Low: $34.21
High: $35.93

50 Day Range

MA: $31.65
Low: $27.69
High: $35.02

2 Week Range

Now: $35.01
Low: $9.22
High: $36.00

Volume

499,774 shs

Average Volume

1,040,263 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1